| Olaparib plus bevacizumab as first-line maintenance in ovarian cancer I Ray-Coquard, P Pautier, S Pignata, D Pérol, A González-Martín, ... New England Journal of Medicine 381 (25), 2416-2428, 2019 | 1843 | 2019 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised … E Pujade-Lauraine, JA Ledermann, F Selle, V Gebski, RT Penson, ... The lancet oncology 18 (9), 1274-1284, 2017 | 1819 | 2017 |
| Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial RL Coleman, AM Oza, D Lorusso, C Aghajanian, A Oaknin, A Dean, ... The Lancet 390 (10106), 1949-1961, 2017 | 1771 | 2017 |
| Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients SA Curley, F Izzo, P Delrio, LM Ellis, J Granchi, P Vallone, F Fiore, ... Annals of surgery 230 (1), 1, 1999 | 1593 | 1999 |
| ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease N Colombo, C Sessa, A du Bois, J Ledermann, WG McCluggage, ... International Journal of Gynecological Cancer 29 (4), 728-760, 2019 | 1277 | 2019 |
| The European Society of Gynaecological Oncology/European Society for Radiotherapy and Oncology/European Society of Pathology guidelines for the management of patients with … D Cibula, R Pötter, F Planchamp, E Avall-Lundqvist, D Fischerova, ... Virchows Archiv 472, 919-936, 2018 | 1037 | 2018 |
| Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse E Pujade-Lauraine, U Wagner, E Aavall-Lundqvist, V Gebski, M Heywood, ... Journal of clinical oncology 28 (20), 3323-3329, 2010 | 736 | 2010 |
| Lenvatinib plus pembrolizumab for advanced endometrial cancer V Makker, N Colombo, A Casado Herráez, AD Santin, E Colomba, ... New England Journal of Medicine 386 (5), 437-448, 2022 | 686 | 2022 |
| Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study UA Matulonis, R Shapira-Frommer, AD Santin, AS Lisyanskaya, S Pignata, ... Annals of Oncology 30 (7), 1080-1087, 2019 | 671 | 2019 |
| Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients SA Curley, P Marra, K Beaty, LM Ellis, JN Vauthey, EK Abdalla, C Scaife, ... Annals of surgery 239 (4), 450-458, 2004 | 484 | 2004 |
| Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial S Pignata, G Scambia, D Katsaros, C Gallo, E Pujade-Lauraine, ... The Lancet Oncology 15 (4), 396-405, 2014 | 431 | 2014 |
| Incorporation of pazopanib in maintenance therapy of ovarian cancer A Du Bois, A Floquet, JW Kim, J Rau, JM Del Campo, M Friedlander, ... Journal of clinical oncology 32 (30), 3374-3382, 2014 | 392 | 2014 |
| Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer G Ferrandina, M Ludovisi, D Lorusso, S Pignata, E Breda, A Savarese, ... Journal of Clinical Oncology 26 (6), 890-896, 2008 | 380 | 2008 |
| Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double … A Poveda, A Floquet, JA Ledermann, R Asher, RT Penson, AM Oza, ... The Lancet Oncology 22 (5), 620-631, 2021 | 364 | 2021 |
| A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients Cancer of the Liver Italian Program (CLIP) Investigators Hepatology 28 (3), 751-755, 1998 | 356 | 1998 |
| Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm … RL Coleman, D Lorusso, C Gennigens, A González-Martín, L Randall, ... The Lancet Oncology 22 (5), 609-619, 2021 | 331 | 2021 |
| The forefront of ovarian cancer therapy: update on PARP inhibitors MR Mirza, RL Coleman, A González-Martín, KN Moore, N Colombo, ... Annals of Oncology 31 (9), 1148-1159, 2020 | 308 | 2020 |
| Treatment of recurrent ovarian cancer S Pignata, SC Cecere, A Du Bois, P Harter, F Heitz Annals of Oncology 28, viii51-viii56, 2017 | 307 | 2017 |
| Atezolizumab, bevacizumab, and chemotherapy for newly diagnosed stage III or IV ovarian cancer: placebo-controlled randomized phase III trial (IMagyn050/GOG 3015/ENGOT-OV39) KN Moore, M Bookman, J Sehouli, A Miller, C Anderson, G Scambia, ... Journal of Clinical Oncology 39 (17), 1842-1855, 2021 | 296 | 2021 |
| Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial S Pignata, G Scambia, G Ferrandina, A Savarese, R Sorio, E Breda, ... Journal of clinical oncology 29 (27), 3628-3635, 2011 | 272 | 2011 |
Francesco PerroneIstituto Nazionale Tumori di Napoliایمیل تأیید شده در istitutotumori.na.it
